Posters

The incidence and outcome of post-cataract surgery cystoid macular oedema (CMO) in an ethnically diverse and predominantly diabetic population

Poster Details

First Author: F.Tsogkas UK

Co Author(s):    S. Patra   N. Kopsachilis           

Abstract Details

Purpose:

To investigate the rate and outcome of cystoid macular oedema (CMO) following cataract surgery in an ethnically diverse and predominantly diabetic population.

Setting:

The Eye treatment centre, Whipps Cross University Hospital, Bartshealth NHS Trust, London, UK.

Methods:

The electronic records of 262 eyes who had uncomplicated cataract surgery in our retina service firm were analysed retrospectively. No eyes received routine post-operative prophylaxis with non-steroidal anti-inflammatory (NSAID) eye drops. Eyes that developed post-operative CMO were treated with a course of ketorolac and dexamethasone 0.1 % eye drops for 6-8 weeks. Our main outcome measures included: (1) Rate of post-operative CMO in the total study population and defined sub-groups (2) Final visual acuity outcome in eyes that developed post-operative CMO.

Results:

There was a history of diabetes in 57%(149/262) of eyes and 58%(152/262) were of Afro-Caribbean and minority ethnic groups (BME). The rest (113/262 and 110/262 respectively) served as a control group. The overall post-operative CMO rate was 7.63%. In eyes with no history of diabetes the post-operative CMO rate was 3.5%. In the sub-group of eyes with pre-operative diabetic retinopathy and normal optical coherence tomogram of the macula a higher rate of 13% post-operative CMO was seen. In BME sub-group the post-operative CMO rate was 10.5%. Of the eyes that developed post-operative CMO 90% achieved ≥6/12 acuity after treatment.

Conclusions:

The rate of post-operative CMO was higher in diabetic patients and patients from the BME population. The majority of eyes treated with NSAID eye drops for post-operative CMO achieved a good final visual outcome. FINANCIAL DISCLOUSRE: NONE